000132270 001__ 132270
000132270 005__ 20240301161207.0
000132270 0247_ $$2doi$$a10.3390/ijms25031549
000132270 0248_ $$2sideral$$a137440
000132270 037__ $$aART-2024-137440
000132270 041__ $$aeng
000132270 100__ $$0(orcid)0000-0002-7277-4318$$aMoreno-Martinez, Laura$$uUniversidad de Zaragoza
000132270 245__ $$aNew Insights into Endogenous Retrovirus-K Transcripts in Amyotrophic Lateral Sclerosis
000132270 260__ $$c2024
000132270 5060_ $$aAccess copy available to the general public$$fUnrestricted
000132270 5203_ $$aRetroviral reverse transcriptase activity and the increased expression of human endogenous retroviruses (HERVs) are associated with amyotrophic lateral sclerosis (ALS). We were interested in confirming HERVK overexpression in the ALS brain, its use as an accessory diagnostic marker for ALS, and its potential interplay with neuroinflammation. Using qPCR to analyze HERVK expression in peripheral blood mononuclear cells (PBMCs) and in postmortem brain samples from ALS patients, no significant differences were observed between patients and control subjects. By contrast, we report alterations in the expression patterns of specific HERVK copies, especially in the brainstem. Out of 27 HERVK copies sampled, the relative expression of 17 loci was >1.2-fold changed in samples from ALS patients. In particular, the relative expression of two HERVK copies (Chr3-3 and Chr3-5) was significantly different in brainstem samples from ALS patients compared with controls. Further qPCR analysis of inflammation markers in brain samples revealed a significant increase in NLRP3 levels, while TNFA, IL6, and GZMB showed slight decreases. We cannot confirm global HERVK overexpression in ALS, but we can report the ALS-specific overexpression of selected HERVK copies in the ALS brain. Our data are compatible with the requirement for better patient stratification and support the potential importance of particular HERVK copies in ALS.
000132270 536__ $$9info:eu-repo/grantAgreement/ES/DGA/B05-17D$$9info:eu-repo/grantAgreement/ES/DGA/B46-20R$$9info:eu-repo/grantAgreement/ES/DGA/B46-23R$$9info:eu-repo/grantAgreement/ES/ISCIII/FEDER/PI21-00372$$9info:eu-repo/grantAgreement/ES/ISCIII/PT13-0010-0018
000132270 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000132270 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000132270 700__ $$aMacías-Redondo, Sofía
000132270 700__ $$aStrunk, Mark
000132270 700__ $$aGuillén-Antonini, María Isabel
000132270 700__ $$aLunetta, Christian
000132270 700__ $$aTarlarini, Claudia
000132270 700__ $$aPenco, Silvana
000132270 700__ $$0(orcid)0000-0001-5193-7782$$aCalvo, Ana Cristina$$uUniversidad de Zaragoza
000132270 700__ $$0(orcid)0000-0001-5687-6704$$aOsta, Rosario$$uUniversidad de Zaragoza
000132270 700__ $$aSchoorlemmer, Jon
000132270 7102_ $$11001$$2420$$aUniversidad de Zaragoza$$bDpto. Anatom.,Embri.Genét.Ani.$$cÁrea Genética
000132270 7102_ $$11012$$2315$$aUniversidad de Zaragoza$$bDpto. Farmac.Fisiol.y Med.L.F.$$cÁrea Farmacología
000132270 773__ $$g25, 3 (2024), 1549 [15 pp.]$$pInt. j. mol. sci.$$tInternational Journal of Molecular Sciences$$x1661-6596
000132270 8564_ $$s2138503$$uhttps://zaguan.unizar.es/record/132270/files/texto_completo.pdf$$yVersión publicada
000132270 8564_ $$s2584992$$uhttps://zaguan.unizar.es/record/132270/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000132270 909CO $$ooai:zaguan.unizar.es:132270$$particulos$$pdriver
000132270 951__ $$a2024-03-01-14:53:40
000132270 980__ $$aARTICLE